Daiichi Sankyo Worldwide


RCI Overview

Daiichi Sankyo Life Science Research Centre in India is a research based drug discovery group. RCI is a part of Daiichi Sankyo India Pharma Private Limited (DSIN), which is a wholly owned subsidiary of Daiichi Sankyo Co. Ltd. RCI started its operation in 2010. With strength of more than 150 scientists, RCI focus is in small molecule drug discovery research in the areas of infectious and autoimmune diseases. RCI is equipped with state of the art laboratories for the design, synthesis and evaluation of new chemical entities for biological activity and drug like characteristics using in vitro and in vivo experimental setups.

Drug Discovery - Infectious & Autoimmune Disease Programmes
Infectious disease is an important component of RCI's discovery research. A drying pipeline and the emergence of antibiotic resistant strains have made research for novel antibacterial an important global imperative. At RCI, scientists are engaged in designing as well as discovering novel first in class or best in class antibacterial agents.

The incidences of autoimmune diseases having an inflammatory manifestation and degenerative outcome are also on the rise. Scientists at RCI are working towards identifying first in-class molecules that target novel mechanism of action for diseases of the airway, musculoskeletal system, gastrointestinal system and central nervous system.
RCI is open to collaborate with academic institutes and government organizations in the identification of novel biological pathways in area of mutual interest.

Company Profile

As a global company, we aim to constantly extend our business activities.